Inhibrx, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inhibrx, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q1 2024.
  • Inhibrx, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$78.7M, a 60.9% decline year-over-year.
  • Inhibrx, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$271M, a 66.5% decline year-over-year.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$241M, a 66.2% decline from 2022.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$145M, a 77.6% decline from 2021.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$81.8M, a 7.41% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$271M -$78.7M -$29.8M -60.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$241M -$93.6M -$52.7M -129% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$189M -$51.8M -$16.5M -46.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$172M -$47.1M -$9.32M -24.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-09
Q1 2023 -$163M -$48.9M -$17.7M -56.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$145M -$40.9M -$19.7M -93.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$126M -$35.3M -$14.7M -71.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$111M -$37.7M -$17M -82.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$93.7M -$31.3M -$12M -62% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$81.8M -$21.2M -$3.54M -20.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$78.2M -$20.6M -$83K -0.41% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$78.1M -$20.7M -$2.83M -15.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$75.3M -$19.3M +$804K +4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$76.1M -$17.6M -$1.34M -8.24% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$74.8M -$20.5M -$334K -1.66% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$74.4M -$17.9M -$6.8M -61.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$67.6M -$20.1M -$16.2M -422% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$51.4M -$16.3M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$20.2M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$11.1M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-13
Q1 2019 -$3.85M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.